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Introduction
Tissue scarring, characterized by cell activation, excessive de-
position of ECM, and extravascular fi  brin deposition, is con-
sidered a limiting factor for tissue repair. Fibrin, the major 
substrate of the serine protease plasmin, is a provisional ma-
trix deposited after vascular injury (Bugge et al., 1996). The 
two plasminogen activators (PAs), namely tissue plasminogen 
activator (tPA) and urokinase plasminogen activator (uPA) 
and their inhibitors, such as plasminogen activator inhibitor-1 
(PAI-1), are key modulators of scar resolution by spatially and 
temporally regulating the conversion of plasminogen to plasmin 
resulting in fi  brin degradation and ECM remodeling (Lijnen, 
2001). In the peripheral nervous system, previous work by us 
and others showed that inhibition of fi   brinolysis in mice 
 defi  cient in plasminogen or tPA exacerbated axonal damage 
(Akassoglou et al., 2000) and impaired functional recovery 
  after nerve injury (Siconolfi   and Seeds, 2001). In accordance, 
mice defi  cient for fi  brinogen showed increased regenerative 
capacity (Akassoglou et al., 2002). Studies of fi  brin deposition 
in human diseases, in combination with experiments from 
mice defi  cient in plasminogen and PAs, have provided infor-
mation about a wide range of physiological and pathological 
conditions that are exacerbated by defective fi  brin degrada-
tion, such as wound healing, metastasis, atherosclerosis, lung 
ischemia, rheumatoid arthritis, muscle regeneration, and mul-
tiple sclerosis (MS) (Degen et al., 2001; Adams et al., 2004). 
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C
learance of ﬁ   brin through proteolytic degrada-
tion is a critical step of matrix remodeling that 
contributes to tissue repair in a variety of patho-
logical conditions, such as stroke, atherosclerosis, and 
pulmonary disease. However, the molecular mechanisms 
that regulate ﬁ  brin deposition are not known. Here, we 
report that the p75 neurotrophin receptor (p75
NTR), a TNF 
receptor superfamily member up-regulated after tissue 
injury, blocks ﬁ  brinolysis by down-regulating the serine 
protease, tissue plasminogen activator (tPA), and up-
regulating plasminogen activator inhibitor-1 (PAI-1). 
We have discovered a new mechanism in which phospho-
diesterase PDE4A4/5 interacts with p75
NTR to enhance 
cAMP degradation. The p75
NTR-dependent down-regulation 
of cAMP results in a decrease in extracellular proteolytic 
activity. This mechanism is supported in vivo in p75
NTR-
deﬁ   cient mice, which show increased proteolysis after 
sciatic nerve injury and lung ﬁ  brosis. Our results reveal a 
novel pathogenic mechanism by which p75
NTR regulates 
degradation of cAMP and perpetuates scar formation 
  after injury.
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However, the molecular mechanisms that regulate proteolytic 
activity remain unclear.
In our current work, we focus on the mechanisms that reg-
ulate fi  brinolysis after injury. Our previous studies demonstrated a 
correlation between fi  brin deposition and expression of p75 neuro-
trophin receptor (p75
NTR) after nerve injury (Akassoglou et al., 
2002). Up-regulation of p75
NTR is observed in MS (Dowling 
et al., 1999), stroke (Park et al., 2000), and spinal cord (Beattie 
et al., 2002) and sciatic nerve injury (Taniuchi et al., 1986), 
all of which are associated with fi  brin deposition. p75
NTR is also 
expressed in non-neuronal tissues (Lomen-Hoerth and Shooter, 
1995) and is up-regulated in non-nervous system diseases asso-
ciated with defects in fi  brin degradation, such as atherosclerosis 
(Wang et al., 2000), melanoma formation (Herrmann et al., 
1993), lung infl  ammation (Renz et al., 2004), and liver disease 
(Passino et al., 2007). p75
NTR has been primarily characterized 
as a modulator of cell death (Wang et al., 2000) and differentia-
tion (Passino et al., 2007) in non-neuronal tissues. The expres-
sion of p75
NTR by cell types such as smooth muscle cells and 
hepatic stellate cells, which actively participate in tissue repair 
by migration, and secretion of ECM and extracellular proteases, 
raises the possibility for a functional role of p75
NTR in disease 
pathogenesis that extends beyond apoptosis and differentiation.
We fi nd that p75
NTR is involved in the regulation of proteo-
lytic activity and fi  brin degradation. Mice defi  cient for p75
NTR 
(Lee et al., 1992) show increased proteolytic activity and de-
creased fi  brin deposition in two disease models: sciatic nerve 
injury and lung fi  brosis. p75
NTR regulates proteolytic activity by 
simultaneously down-regulating tPA and up-regulating PAI-1 
via a novel cAMP/PKA pathway. p75
NTR decreases cAMP via 
interaction with the cAMP-specifi  c phosphodiesterase (PDE) 
isoform PDE4A4/5. This is of particular note, as selective PDE4 
inhibitors have an anti-infl  ammatory action and have potential 
therapeutic utility in infl  ammatory lung disease, as well as in a 
wide range of neurologic diseases such as depression, spinal 
cord injury, MS, and stroke (Gretarsdottir et al., 2003; Nikulina 
et al., 2004; Houslay et al., 2005). Overall, the regulation of 
plasminogen activation by p75
NTR identifi  es a novel pathogenic 
mechanism whereby p75
NTR interacts with PDE4A4/5 to de-
grade cAMP and thus perpetuates scar formation that could 
possibly render the environment hostile for tissue repair.
Results
Fibrin deposition is reduced in p75
NTR−/− mice
To examine whether p75
NTR regulates fi  brin deposition in the 
sciatic nerve we compared fi  brin levels in wild-type (wt) and 
p75
NTR−/− mice after injury. In wt mice, there is a dramatic 
  increase of fi  brin deposition (Fig. 1 c) and p75
NTR expression 
(Fig. 1 d) after injury, when compared with uninjured nerves 
(Fig. 1, a and b). In contrast, p75
NTR−/− mice show reduced fi  brin 
deposition after injury (Fig. 1 e). Quantifi  cation of immuno-
blots reveals that p75
NTR−/− mice have decreased fi  brin by three-
fold 3 d and fourfold 8 d after injury (Fig. 1 g). Quantifi  cation 
of fi  brin immunostaining also reveals that p75
NTR−/− mice have 
signifi  cantly decreased fi  brin (Fig. 1 h, P < 0.003). These re-
sults suggest that loss of p75
NTR decreases the levels of fi  brin in 
the sciatic nerve after injury.
p75
NTR regulates expression of tPA 
in the sciatic nerve after crush injury
Analysis of total fi  brinogen levels were similar in the plasma of 
wt and p75
NTR−/− mice (unpublished data), suggesting the de-
crease in fi  brin deposition is not the result of hypofi  brinogenemia. 
Because fi  brin removal depends on proteolytic activity (Bugge 
et al., 1996), we hypothesized that the decreased fi  brin in the 
p75
NTR−/− mice refl  ects an up-regulation of the proteolytic activity. 
p75
NTR−/− mice have increased proteolytic activity (Fig. 2 b) 
Figure 1.  Fibrin deposition is reduced in the 
sciatic nerve of p75
NTR−/− mice. Immunohisto-
chemistry for ﬁ  brin on uninjured wt (a) and 4 d 
after sciatic nerve crush injury wt (c) and 
p75
NTR−/− mice (e). Immunohistochemistry for 
p75
NTR on uninjured wt (b) and 4 d after sciatic 
nerve crush injury wt (d) and p75
NTR−/− mice (f). 
Representative images are shown from n = 
20 wt and n = 20 p75
NTR−/− mice. (g) Western 
blot for p75
NTR and ﬁ  brin on sciatic nerve ex-
tracts from uninjured wt, and wt and p75
NTR−/− 
mice 3 and 8 d after injury. Myosin serves as 
loading control. Western blots were performed 
three times. A representative blot is shown. 
(h) Quantiﬁ   cation of ﬁ   brin deposition shows 
signiﬁ   cant decrease for ﬁ  brin  in  p75
NTR−/− 
mice (n = 5), when compared with wt mice 
(n = 4). Bar graph represents means ± SEM 
(P < 0.003; by t test). Bar, 25 μm. P75
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when compared with wt mice (Fig. 2 a) that is statistically sig-
nifi  cant (Fig. 3 i, P < 0.05). Uninjured nerves exhibit minimal 
proteolytic activity (Fig. 2 i), as expected (Akassoglou et al., 
2000). Injured p75
NTR−/− sciatic nerves do not show lysis of fi  brin 
in the absence of plasminogen (Fig. 2 c), suggesting that the 
proteolytic activity is plasminogen dependent.
The tPA/plasmin system regulates fi  brin clearance after 
nerve injury (Akassoglou et al., 2000). A specifi  c tPA inhibitor, 
tPASTOP, blocks proteolytic activity in p75
NTR−/− mice (Fig. 2 d). 
p75
NTR is strongly activated by withdrawal of axons (Lemke and 
Chao, 1988) and its expression correlates with proliferating, 
non-myelin producing Schwann cells (SCs) (Zorick and Lemke, 
1996). After sciatic nerve injury both p75
NTR (Fig. 2 e, red) 
and tPA (Fig. 2 e, green) increase when compared with un-
injured controls (Fig. 2 j), but show little colocalization (Fig. 2, 
e and h), suggesting that p75
NTR-reexpressing SCs do not ex-
press tPA. Expression of tPA (Fig. 2 k, red) and p75
NTR (Fig. 2 l, 
red) in SCs is confi  rmed using double immunofl  uorescence 
with the SC marker S100 (Fig. 2, k and l; green).
Genetic loss of tPA rescues the effects 
of p75
NTR deﬁ  ciency
To examine genetically whether the increased proteolytic activ-
ity in the p75
NTR−/− mice was due to tPA, we crossed p75
NTR−/− 
mice with tPA
−/− mice and generated p75
NTR−/−tPA
−/− double-
knockout mice. p75
NTR−/− mice show a decrease in fi  brin depo-
sition (Fig. 3 b) and an increase in proteolytic activity (Fig. 3 f), 
compared with wt control mice (Fig. 3, a and e, respectively). 
In contrast, p75
NTR−/−tPA
−/− mice show increased fi  brin deposi-
tion (Fig. 3 c) when compared with p75
NTR−/− mice (Fig. 3 b) 
and no evidence of proteolytic activity (Fig. 3 g). As a control, 
tPA
−/− mice also show no evidence of proteolytic activity after 
sciatic nerve crush injury (Fig. 3 h), as described previously 
(Akassoglou et al., 2000). Quantifi  cation of proteolytic activity 
is shown in Fig. 3 i. The evidence derived from the genetic de-
pletion of tPA in the p75
NTR−/− mice (p75
NTR−/−tPA
−/− mice, 
Fig. 3 g) are in accordance with the pharmacologic inhibition of 
tPA activity in the p75
NTR−/− sciatic nerve using tPASTOP (Fig. 
2 d). Overall, these results suggest that up-regulation of proteo-
lytic activity in the sciatic nerve of p75
NTR−/− mice is due to up-
regulation of tPA.
p75
NTR−/− SCs show increased expression 
of tPA and increased ﬁ  brinolysis
Because SCs are a major source for tPA after injury, we isolated 
primary SCs from wt and p75
NTR−/− mice and cultured them on 
a three-dimensional (3D) fi  brin gel. Wt SCs, which express high 
levels of p75
NTR, form a monolayer on the fi  brin gel (Fig. 4 a). 
In contrast, p75
NTR−/− SCs degrade the fi  brin gel (Fig. 4 b) and 
show a 2.7-fold increase of fi   brin degradation (Fig. 4 c). 
p75
NTR−/− SCs show a sixfold increase in tPA levels, when com-
pared with wt SCs (Fig. 4 d; P < 0.01). These results suggest 
that p75
NTR down-regulates tPA activity and blocks fi  brin degra-
dation in SCs in vitro.
Expression of p75
NTR inhibits tPA 
and ﬁ  brinolysis
After fi  nding a biological function for p75
NTR in the regulation 
of tPA using SCs and sciatic nerves from p75
NTR−/− mice, we 
used stable and transient transfections of p75
NTR as well as 
Figure 2. p75
NTR regulates expression of tPA in the sciatic nerve after crush injury. In situ zymography in the presence of plasminogen on wt (a) and 
p75
NTR−/− (b) mice and in the absence of plasminogen (c) or in the presence of plasminogen and tPASTOP (d) in p75
NTR−/− mice. Arrows indicate the lytic 
zone. Double immunoﬂ  uorescence for tPA (green) or p75
NTR (red) on wt (e and h), p75
NTR−/− (f) and p75
NTR−/−tPA
−/− mice (g). Uninjured wt sciatic nerve 
exhibits minimal proteolytic activity (i) and minimal tPA and p75
NTR immunoreactivity (j). Zymographies have been performed on n = 10 wt and n = 10 
p75
NTR−/− mice. Representative images are shown. tPA (k) and p75
NTR (l) expression in SCs was veriﬁ  ed by double immunoﬂ  uorescence with an S100 (SC 
marker) antibody. Arrows indicate double-positive cells (k and l, yellow). The experiment was repeated at two different time points (4 and 8 d after crush 
  injury) in n = 4 mice per genotype per time point and representative images are shown. Bar: 400 μm (a  –d, i), 150 μm (e–g, j), 20 μm (h, k, and l). JCB • VOLUME 177 • NUMBER 6 • 2007  1122
siRNA against p75
NTR to test the properties of p75
NTR in heterol-
ogous systems. To examine whether p75
NTR could inhibit fi  brin 
degradation, we fi  rst used NIH3T3 fi  broblasts stably transfected 
with p75
NTR that exhibit high levels of p75
NTR (10
5 receptors/
cell) (Hsu and Chao, 1993). NIH3T3 cells on a 3D fi  brin gel 
degrade fi  brin (Fig. 5 a), whereas NIH3T3p75
NTR cells do not 
(Fig. 5 b). Expression of p75
NTR inhibits fi  brin degradation by 
12-fold (Fig. 5 c; P < 0.001). NIH3T3 cells form lytic areas 
(Fig. 5 d), whereas NIH3T3p75
NTR cells grow uniformly on fi  brin 
(Fig. 5 e). NIH3T3 cells fully degrade the plasmin substrate 
  casein (Fig. 5 f) but NIH3T3p75
NTR cells do not degrade casein 
(Fig. 5 g), suggesting impaired proteolysis in NIH3T3p75
NTR cells. 
Aprotinin, a general inhibitor of serine proteases, completely 
inhibits fi  brin degradation by NIH3T3 cells (not depicted). 
In fi  broblasts both tPA and uPA are involved in activation of 
plasminogen and fi  brin degradation. tPA activity is signifi  cantly 
decreased in the NIH3T3p75
NTR cells (Fig. 5 h). In contrast, 
  expression of p75
NTR has no effect on uPA activity (Fig. 5 i).
tPA is a transcriptionally regulated immediate-early gene 
(Qian et al., 1993). Indeed, expression of p75
NTR down-regulates 
tPA transcripts (Fig. 5 j). In addition, mRNA of PAI-1 is also up-
regulated in NIH3T3p75
NTR cells (Fig. 5 j). Real-time quantita-
tive PCR shows a 10.1-fold decrease in tPA mRNA, a fourfold 
increase in PAI-1 mRNA, and a twofold decrease in uPA mRNA 
in NIH3T3p75
NTR cells. Upon expression of p75
NTR, the decrease 
of uPA RNA does not affect uPA activity (Fig. 5 i). In contrast, 
the decrease of tPA RNA in NIH3T3p75
NTR cells results in a 
  corresponding decrease in tPA activity (Fig. 5 h; P < 0.01). 
Figure 3.  Loss of tPA rescues the effects of p75
NTR deﬁ  ciency in plasminogen activation and ﬁ  brin deposition in the sciatic nerve. Increased ﬁ  brin deposition 
in the crushed sciatic nerve of p75
NTR−/−tPA
−/− mice (c), when compared with crushed p75
NTR−/− sciatic nerve (b). Wt (a) and tPA
−/− (d) nerves are used for 
control. In situ zymography shows lack of proteolytic activity in the crushed p75
NTR−/−tPA
−/− sciatic nerves (n = 5) (g), when compared with crushed p75
NTR−/− 
sciatic nerves (n = 20) (f). Crushed wt (e) and tPA
−/− (h) nerves are used for control. Fibrin immunostainings and zymographies were performed on n = 5 
p75
NTR−/−tPA
−/−, n = 20 p75
NTR−/−, n = 20 wt, n = 5 tPA
−/− mice. Representative images are shown. (i) Quantiﬁ  cation of proteolytic activity 4 d after crush 
injury shows statistically signiﬁ  cant increase for proteolytic activity in p75
NTR−/− mice. Quantiﬁ  cation results are based on n = 5 p75
NTR−/−, n = 5 p75
NTR−/− 
tPA
−/−, n = 5 tPA
−/− and n = 4 wt mice. Bar graph represents means ± SEM (*, P < 0.05; by ANOVA). Bar: 50 μm (a–d), 300 μm (e–h). 
Figure 4. p75
NTR-mediated regulation of tPA and ﬁ   brinolysis in SCs. 
Primary SC cultures from wt (a) or p75
NTR−/− mice (b) on a 3D ﬁ  brin gel. 
Arrowheads indicate the border of ﬁ  brin degradation. Quantiﬁ  cation of 
  ﬁ   brin degradation (c) and tPA activity (d) from wt and p75
NTR−/− SCs. 
Experiments were performed three times in duplicates. Representative im-
ages are shown. Bar graph represents means ± SEM (P < 0.01; by t test). 
Bar, 130 μm.P75
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After injury, sciatic nerves of p75
NTR−/− mice show a fourfold in-
crease of tPA RNA when compared with wt (Fig. 5 k). More-
over, p75
NTR−/− mice show an increase in tPA RNA in primary 
cerebellar granule neurons (CGNs) (Fig. S1 c, available at 
http://www.jcb.org/cgi/content/full/jcb.200701040/DC1), and 
increased proteolytic activity in the cerebellum (Fig. S1, a and b). 
Overall, these data suggest that expression of p75
NTR inhibits the 
tPA/plasmin system both in vivo in the cerebellum and after sci-
atic nerve injury, as well as in vitro in primary neurons, SCs, as 
well as fi  broblasts.
p75
NTR regulates tPA and PAI-1 
via a PDE4/cAMP/PKA pathway
Transcriptional regulation of tPA depends on the cAMP/PKA 
pathway (Medcalf et al., 1990). Indeed, elevation of cAMP, 
  using dibutyryl-cAMP (db-cAMP), overcomes the inhibitory 
effect of p75
NTR (Fig. 6 a). Moreover, cAMP elevation, elicited 
using the general PDE inhibitor IBMX, elevates tPA activity in 
NIH3T3p75
NTR to the levels seen in NIH3T3 cells (Fig. 6 b). 
IBMX does not affect basal levels of tPA in NIH3T3 cells (Fig. 6 b). 
These data suggest that PDE activity is required for the p75
NTR-
induced tPA decrease.
PKA activity is decreased in NIH3T3p75
NTR cells (Fig. 6 c, 
lanes 3 and 4) compared with NIH3T3 cells (Fig. 6 c, lanes 1 
and 2), suggesting that p75
NTR expression reduces PKA activity. 
KT5720, a specifi  c PKA inhibitor, decreases tPA activity in 
NIH3T3 cells (Fig. 6 b). Because the cAMP/PKA pathway 
  enhances tPA transcription and suppresses PAI-1 secretion 
(Santell and Levin, 1988), we tested whether the cAMP/PKA 
pathway infl  uences the p75
NTR regulation of tPA and PAI-1. 
Forskolin-induced cAMP elevation increases, whereas KT5720-
induced PKA inhibition decreases tPA RNA in NIH3T3 cells 
(Fig. 6 d). Forskolin treatment of NIH3T3p75
NTR cells also in-
creases both tPA RNA (Fig. 6 d) and activity (not depicted), 
whereas forskolin decreases PAI-1 RNA in both NIH3T3 and 
NIH3T3p75
NTR cells (Fig. 6 e).
Similar to NIH3T3 cells, elevation of cAMP increases the 
activity of tPA in both wt and p75
NTR−/− SCs (Fig. 6 f). Brain-
  derived neurotrophic factor (BDNF)/TrkB signaling has been 
shown to regulate tPA in primary cortical neurons (Fiumelli 
et al., 1999). In contrast to cortical neurons, SCs are known to 
express minute levels of TrkB but high levels of p75
NTR (Cosgaya 
et al., 2002). We show here that treatment of SCs with either 
BDNF or nerve growth factor (NGF) has no effect on tPA (Fig. 6 f). 
Similar results are obtained after treatment of SCs with pro-
NGF, the high-affi  nity ligand of p75
NTR (Lee et al., 2001) (un-
published data). In addition, in NIH3T3 and NIH3T3p75
NTR 
cells, which do not express Trk receptors, the p75
NTR-mediated 
suppression of tPA activity occurs independent of neurotrophins 
or serum (unpublished data). In accordance, in NIH3T3 cells 
transient expression of the intracellular domain (ICD) of p75
NTR 
decreases tPA similar to the full-length (FL) p75
NTR (Fig. 6 g). 
Figure 5.  Expression of p75
NTR regulates tPA, PAI-1, and ﬁ  brinolysis in ﬁ  broblasts. 3D ﬁ  brin gel degraded by NIH3T3 (a), but not by NIH3T3p75
NTR cells (b). 
(c) Quantiﬁ  cation of ﬁ  brin degradation. Experiments were performed seven times in duplicates. Phase-contrast microscopy shows lytic zones in NIH3T3 (d), 
but not in NIH3T3p75
NTR cultures (e). Zymography shows degradation of casein by NIH3T3 cells (f), whereas NIH3T3p75
NTR cells do not degrade 
casein (g). Quantiﬁ  cation of tPA (h) and uPA (i) activity in supernatants from NIH3T3 and NIH3T3p75
NTR cultures. Experiments were performed ﬁ  ve times in 
duplicates. (j) RT-PCR analysis for tPA, PAI-1, uPA, and GAPDH on cDNA derived from NIH3T3 and NIH3T3p75
NTR cells. (k) RT-PCR analysis for tPA and 
GAPDH on cDNA derived from uninjured wt, and wt or p75
NTR−/− mice three days after nerve injury. Bar graphs represent means ± SEM (statistics by 
t test). Bar: 1.2 cm (a and b), 130 μm (d–g).JCB • VOLUME 177 • NUMBER 6 • 2007  1124
These data suggest that neurotrophin/p75
NTR signaling is not in-
volved in the regulation of tPA in SCs and fi  broblasts and that 
regulation of tPA by p75
NTR is independent of neurotrophins.
p75
NTR decreases cAMP via PDE4
Because the effects of p75
NTR were overcome by elevating 
cAMP, we examined whether p75
NTR reduced cAMP levels. 
  Indeed, cAMP is decreased 7.8-fold in NIH3T3p75
NTR cells 
(Fig. 7 a; P < 0.0001). Transient expression of p75
NTR in NIH3T3 
cells decreases levels of cAMP (Fig. 7 b; P < 0.0005).
Furthermore, siRNA knockdown against p75
NTR leads to in-
creased cAMP levels in both NIH3T3p75
NTR cells (Fig. 7, c and e; 
P < 0.02) and primary SCs (Fig. 7, d and f; P < 0.03). 
NIH3T3 cells transiently transfected with p75
NTR express fi  ve-
fold less p75
NTR than the stably transfected NIH3T3p75
NTR cells 
(unpublished data). Differences in expression between stably 
and transiently transfected cells may account for the differ-
ences in the fold-decrease of cAMP and tPA between these two 
systems. Moreover, immunostaining with an antibody against 
cAMP shows increased cAMP in injured sciatic nerves from 
p75
NTR−/− mice (Fig. 7, g and h). In neurons BDNF elevates 
cAMP exclusively via TrkB (Gao et al., 2003). In NIH3T3p75
NTR 
cells, which do not express TrkB, stimulation with NGF or 
BDNF does not affect the p75
NTR-mediated suppression of 
cAMP (Fig. S2). Similarly, inhibition of neurotrophins by 
Fc-p75
NTR or BDNF by Fc-TrkB does not alter cAMP levels in 
NIH3T3p75
NTR cells (Fig. S2, available at http://www.jcb.org/
cgi/content/full/jcb.200701040/DC1). In accordance, transient 
expression of the ICD of p75
NTR decreases cAMP similar to the 
FL p75
NTR in NIH3T3 cells (Fig. 7 b). Overall, these data sug-
gest a neurotrophin-independent PDE4/cAMP pathway down-
stream of p75
NTR, which consequently leads to decreases in 
extracellular proteolysis.
Down-regulation of cAMP can be mediated either by in-
hibition of cAMP synthesis via the action of Gi, a G protein that 
inhibits adenylyl cyclase or via the action of PDEs. Treatment 
of cells with pertussis toxin (PTX) that blocks interactions be-
tween the Gi and G protein coupled receptors, does not rescue 
the p75
NTR-mediated down-regulation of cAMP (Fig. 7 a; 
P > 0.5). In contrast, the PDE inhibitor IBMX resulted in sig-
nifi  cant increase of cAMP in the NIH3T3p75
NTR cells when 
compared with control NIH3T3p75
NTR cells (Fig. 7 a; P < 
0.000001). Use of specifi  c chemical inhibitors for PDE iso-
forms shows that only rolipram, a specifi  c inhibitor of PDE4, 
signifi  cantly increases cAMP levels in NIH3T3p75
NTR cells 
(Fig. 7 a; P < 0.000001) to the levels of NIH3T3 cells (Fig. 7 a; 
P = 0.051), suggesting that the p75
NTR-induced cAMP decrease 
is mediated via PDE4.
Figure 6. p75
NTR regulates tPA and PAI-1 via a PDE4/cAMP/PKA pathway. (a) db-cAMP induces ﬁ  brinolysis in NIH3T3p75
NTR cells. (b) IBMX increases 
tPA activity of NIH3T3p75
NTR cells to the levels of NIH3T3 cells. Inhibition of PKA by KT5720 shows decrease of tPA activity in both NIH3T3 and 
NIH3T3p75
NTR cells (P < 0.0001). (c) PKA activity assay shows decrease of PKA in NIH3T3p75
NTR cells. (d) Forskolin increases tPA mRNA in NIH3T3 and 
NIH3T3p75
NTR cells. Inhibition of PKA by KT5720 decreases tPA transcript. (e) Quantiﬁ  cation of PAI-1 mRNA changes by real time PCR shows a fourfold 
increase of PAI-1 mRNA in NIH3T3p75
NTR cells compared with NIH3T3 cells. (f) Forskolin increases tPA activity in both wt (P<0.001) and p75
NTR−/− (P < 
0.00001) SCs. NGF and BDNF do not affect activity of tPA (P > 0.8 and P > 0.3, respectively). (g) Transient overexpression of FL p75
NTR or p75 ICD 
leads to decreased levels of tPA in NIH3T3 cells. Experiments were performed at least 5 times in duplicates. *, P < 0.0001; **, P < 0.05; ***, P < 0.01. 
NS: non-signiﬁ  cant. Bar graphs represent means ± SEM (statistics by ANOVA).P75
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p75
NTR interacts with PDE4A4/5 
and targets cAMP degradation 
to the membrane
Recruitment of PDE4 to subcellular structures such as the 
plasma membrane concentrates the activity of PDEs and re-
duces PKA activity by enhancing degradation of cAMP (Brunton, 
2003; Houslay and Adams, 2003). We therefore examined 
whether p75
NTR regulates cAMP via recruitment of PDE4. In 
NIH3T3p75
NTR cells, p75
NTR coimmunoprecipitates (co-IPs) with 
endogenous PDE4A (Fig. 8 a). No association is observed with 
the other three PDE4 sub-families, namely PDE4B, PDE4C, 
or PDE4D (unpublished data), suggesting that the effect was 
PDE4A specifi  c. Based on the molecular weight of PDE4A at 
109 kD, we determined that p75
NTR co-IPs with the PDE4A5 
isoform. Endogenous co-IP in CGNs (Fig. S3 a, available at 
http://www.jcb.org/cgi/content/full/jcb.200701040/DC1) and in 
injured sciatic nerve (Fig S3 b) shows that p75
NTR and PDE4A5 
interact at endogenous expression levels. Analysis of lysates 
shows that the levels of PDE4A are similar in NIH3T3 and NI-
H3T3p75
NTR cells (Fig. S3 c). These results show that p75
NTR 
forms a complex with PDE4A5.
A functional consequence of the p75
NTR–PDE4A5 inter-
action would be recruitment of PDE4A5 to the membrane re-
sulting in decreased membrane-associated cAMP/PKA signaling. 
To investigate whether p75
NTR reduces membrane-associated 
PKA activity, we modifi  ed the genetically encoded A-kinase 
activity reporter, AKAR2 (Zhang et al., 2005) and generated 
pm-AKAR2.2, a membrane-targeted fl  uorescent reporter of 
PKA activity that generates a change in fl  uorescence reso-
nance energy transfer (FRET) when it is phosphorylated by 
PKA in living cells (Fig. S4 a). As expected, NIH3T3 cells 
show a dramatic emission ratio change for the pm-AKAR2.2 
in response to forskolin (Fig. 8 b). In contrast, NIH3T3p75
NTR 
cells show an attenuated response, revealing reduced PKA 
activity at the plasma membrane (Fig. 8 b). Transient trans-
fection of p75
NTR confi  rmed the results observed in the stable 
NIH3T3p75
NTR cells using the latest generation of plasma 
 membrane–specifi  c PKA biosensor AKAR3 (Allen and Zhang, 
2006) (Fig. S4 b, available at http://www. jcb.org/cgi/content/
full/jcb.200701040/DC1). As expected, increased cAMP degra-
dation at the plasma membrane results in decreased intracel-
lular cAMP (Fig. S4 c; Fig. 7, a and b). Overall, our results 
showing reduced membrane-associated PKA activity upon 
expression of p75
NTR suggest that p75
NTR targets cAMP deg-
radation to the membrane via its interaction with PDE4A5.
To verify the specifi  city of p75
NTR–PDE4A5 association, a se-
ries of mapping studies were conducted using deletion mutants. 
PDE4A5 interacts with FL p75
NTR, as well as deletions ∆3, ∆62, 
Figure 7. p75
NTR decreases intracellular cAMP via PDE4. 
(a) cAMP levels in NIH3T3 and NIH3T3p75
NTR cells show 
a reduction of cAMP in NIH3T3p75
NTR cells, as compared 
with NIH3T3 cells. Treatment with PTX, IBMX, speciﬁ  c 
  inhibitors for PDE1, PDE2, PDE3, and PDE4 (rolipram) 
shows that only IBMX (IC50 for PDE4 2–50 μM) and ro-
lipram (IC50 for PDE4 0.8 μM) (P < 0.0001) increase 
levels of cAMP in NIH3T3p75
NTR cells to the levels of 
NIH3T3 cells. (b) Transient overexpression of FL p75
NTR or 
p75 ICD leads to decreased levels of cAMP in NIH3T3 
cells. (c) siRNA mediated knockdown of p75
NTR levels in 
NIH3T3p75
NTR cells leads to increased levels of cAMP. 
(d) siRNA mediated knockdown of p75
NTR in primary rat 
Schwann cells leads to increased levels of cAMP. p75
NTR 
levels after siRNA knock down in duplicate samples of 
NIH3T3p75
NTR cells (e) and SCs (f). Immunostaining to de-
tect cAMP in injured sciatic nerve reveals increased cAMP 
immunoreactivity in the sciatic nerve of p75
NTR−/− mice (h) 
when compared with wt controls (g). Experiments were 
performed four times in duplicate. Bar graphs represent 
means ± SEM (statistics by ANOVA or t test). JCB • VOLUME 177 • NUMBER 6 • 2007  1126
∆83, but not a deletion missing the distal 151 amino acids, ∆151 
(Fig. 8 c), suggesting that the interaction between p75
NTR and 
PDE4A5 occurs in the juxtamembrane region of p75
NTR, requir-
ing sequences between residues 275 and 343. To explain the 
specifi  city of the interaction of p75
NTR with a single PDE4 iso-
form, we reasoned that p75
NTR would interact with a unique region 
of PDE4A5 that is not present in other PDE4s. Although the 
PDE4 isoforms are highly homologous, PDE4A5 contains a 
unique C-terminal region with a yet unknown biological function 
(Houslay and Adams, 2003). Co-IP experiments in HEK293 cells 
us ing the PDE4A4δCT mutant that is missing the C-terminal region 
(aa 721–886) abolishes the interaction with p75
NTR (Fig. 8 d).
To examine whether p75
NTR could interact with PDE4A5 in 
a direct manner, we performed in vitro pull-down assays using re-
combinant proteins. A GST fusion protein of p75
NTR encoding the 
entire ICD interacts with both recombinant PDE4A5 and its hu-
man homologue PDE4A4 (Fig. 8 e). In contrast, p75
NTR ICD does 
not interact with recombinant PDE4D3 (Fig. 8 e). These results 
are in accordance with both the endogenous co-IPs in cells (Fig. 
8, a and c; Fig. S3) and the PDE4A4 mutagenesis data (Fig. 8 d) 
because similar to PDE4A4δCT, PDE4D3 does not contain the 
unique C-terminal domain of PDE4A4/5. We have used peptide 
array technology to defi  ne sites of direct interaction in other 
PDE4s (Bolger et al., 2006). Screening a peptide array library 
of overlapping 25-mer peptides that scanned the sequence of 
PDE4A4 with GST-ICD p75
NTR identifi  ed interactions with the 
LR1 domain, whose sequence is unique to the PDE4A subfamily 
(peptides 40 and 41, aa 191–220), and also to a sequence within 
the catalytic domain (peptides 135 and 136, aa 671–700). How-
ever, the strongest interaction was observed with sequences within 
the C-terminal region of PDE4A4 (peptides 172 and 173, aa 856–
885). Alanine scanning mutagenesis shows that substitution of 
C862 abolishes the interaction of p75
NTR with the 173 peptide that 
is unique to PDE4A (Fig. 8 g). The p75
NTR-interacting sequences 
within the LR1 and C-terminal domains are highly conserved 
  between the human PDE4A4 and the rodent PDE4A5. Indeed, 
peptide array screening for PDE4A5 reveals direct interaction 
with p75
NTR similar to that seen for PDE4A4 (unpublished data). 
Overall, these results suggest that the interaction of p75
NTR with 
PDE4A4/5 is direct and that sequences within the juxtamembrane 
region of p75
NTR and the unique C-terminal region of PDE4A4/5 
are primarily required for the interaction (Fig. 8, a, c–g; Fig. S3).
Figure 8. p75
NTR interacts with PDE4A4/5. (a) Endoge-
nous PDE4A5 co-IPs with p75
NTR in NIH3T3p75
NTR cells. 
Lysates were immunoprecipitated with anti-p75
NTR and 
probed with anti-PDE4A or anti-p75
NTR. Due to the low 
endogenous levels of PDE4A, higher exposure was ne-
cessary to detect PDE4A5 in the lysates (see Fig. S3 c). 
(b) FRET emission ratio change of NIH3T3 and NIH3T3p75
NTR 
cells for the pm-AKAR2.2 in response to forskolin. FRET 
change represents membrane activation of PKA (c) Map-
ping of the p75
NTR sites required for interaction with 
PDE4A5. Schematic diagram of HA-tagged p75
NTR intra-
cellular deletions. TM, transmembrane domain; DD, death 
domain. Lysates were immunoprecipitated with an anti-
HA antibody and probed with anti-PDE4A or anti-p75
NTR. 
(d) Mapping of the PDE4A4 sites required for interaction 
with p75
NTR. Schematic diagram of the C-terminal dele-
tion of PDE4A4. Arrow indicates the deletion site. Lysates 
were immunoprecipitated with anti-p75
NTR and probed 
with anti-PDE4A or anti-p75
NTR. (e) Co-IP of puriﬁ  ed, re-
combinant proteins reveals that both PDE4A4 and 
PDE4A5 interact with the ICD of p75
NTR, but PDE4D3 
does not. (f) PDE4A4 peptide library screened with re-
combinant GST-p75
NTR ICD revealed three distinct do-
mains of PDE4A4 (asterisks in d) that interact with the ICD 
of p75
NTR: the LR1 domain (peptides 40 and 41), the cat-
alytic domain (peptides 135 and 136) and the unique C 
terminus (peptides 172 and 173). (g) Alanine scanning 
mutagenesis shows that substitution of C862 abolishes 
the interaction of p75
NTR with the 173 peptide that is 
unique to PDE4A. P75
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p75
NTR regulates plasminogen activation 
and ﬁ  brin deposition in a model 
of lipopolysaccharide-induced 
pulmonary ﬁ  brosis
Because expression of p75
NTR inhibits fi  brinolysis in fi  broblasts, 
we hypothesized that the role of p75
NTR as a modulator of fi  brino-
lysis extends to tissues outside of the nervous system that ex-
press p75
NTR after injury or disease. Because p75
NTR is expressed 
in the lung (Ricci et al., 2004), we compared the levels of fi  brin 
in the lung of wt and p75
NTR−/− mice in a model of lipopoly-
saccharide (LPS)-induced lung fi  brosis (Chen et al., 2004). 
LPS-treated wt mice showed widespread extravascular fi  brin 
deposition (Fig. 9 b) and decreased proteolytic activity after 
LPS treatment (Fig. 9 e), when compared with saline-treated wt 
mice (Fig. 9, a and d). In contrast, p75
NTR−/− mice show a 2.58-
fold decrease of fi  brin immunoreactivity (Fig. 9, c and j) and 
increased proteolytic activity (Fig. 9 f).
Decreased proteolytic activity in the lung after injury de-
pends on the up-regulation of PAI-1 (Idell, 2003). Loss of PAI-1 
protects from pulmonary fi  brosis in LPS-induced airway dis-
ease, hyperoxia, and bleomycin-induced fi  brosis (Savov et al., 
2003). Because p75
NTR increases PAI-1 (Fig. 5 j and Fig. 6 e), we 
examined whether p75
NTR regulates expression of PAI-1 in vivo. 
PAI-1 is up-regulated in LPS-treated wt mice (Fig. 9 h) when 
compared with saline-treated wt mice (Fig. 9 g). In contrast, 
LPS-treated p75
NTR−/− mice show similar immunoreactivity for 
PAI-1 (Fig. 9 i) as saline-treated wt mice (Fig. 9 g), suggesting 
that p75
NTR induces up-regulation of PAI-1 after injury in the lung. 
Western blots show a decrease in PAI-1 in the lungs of p75
NTR−/− 
mice (Fig. 9 k). Similar to the p75
NTR−/− mice, rolipram reduces 
fi  brin deposition in the lung (Fig. S5, a and b; available at http://
www.jcb.org/cgi/content/full/jcb.200701040/DC1) and sciatic 
nerve (Fig. S5, d–f), and decreases PAI-1 in the lung (Fig. S5 c), 
suggesting the involvement of PDE4 in p75
NTR-mediated inhibi-
tion of fi  brinolysis in vivo. Collectively, our data show that 
p75
NTR increases fi  brin deposition via a PDE4-mediated inhibi-
tion of plasminogen activation in both LPS-induced lung fi  brosis 
and sciatic nerve crush injury. These data suggest a role for 
p75
NTR/PDE4 signaling as a general regulator of plasminogen 
activation and fi  brinolysis at sites of injury.
Discussion
Our study shows a novel direct interaction of p75
NTR with 
PDE4A4/5, a specifi  c PDE4 isoform, which results in the regu-
lation of cAMP, a major intracellular signaling pathway, and 
mediates a major biological function of extracellular prote-
olysis and fi  brinolysis (Fig. 10). p75
NTR is expressed in a wide 
range of tissue injury models, where repair depends upon both 
cell differentiation and ECM remodeling. For example, we re-
cently showed that in the absence of plasminogen the effects of 
p75
NTR in tissue repair are protective due to its benefi  cial effects 
in cell differentiation (Passino et al., 2007). Similarly, in the 
fl  ow-restricted carotid artery model of vascular injury that 
  depends on uPA and not on tPA-mediated fi  brinolysis (Kawasaki 
et al., 2001), p75
NTR is protective due to the induction of smooth 
Figure 9. p75
NTR regulates ﬁ  brin clearance in the lung. 
LPS induces ﬁ  brin deposition (red) in the wt lung (b), when 
compared with the saline-injected lung (a). Lungs derived 
from p75
NTR−/− mice show less ﬁ  brin deposition (c). In situ 
zymography after 3 h of incubation shows clearance of 
casein in the lung of saline-injected wt (d), when com-
pared with LPS injected wt lung (e). Lung from LPS-treated 
p75
NTR−/− mouse shows enhanced proteolytic activity (f), 
when compared with the wt mouse (e). Immunoreactivity 
for PAI-1 is increased in wt lung derived from LPS-treated 
mouse (h), when compared with saline-treated control (g). 
Lung from LPS-treated p75
NTR−/− mouse shows decreased 
PAI-1 (i), when compared with the wt LPS-treated mouse 
(h). (j) Western blot of ﬁ  brin precipitation from the lung 
shows an up-regulation of ﬁ  brin in the LPS-treated wt lung, 
when compared with the p75
NTR−/− lung. (k) Western blot 
for PAI-1 in the lung shows a decrease of PAI-1 in the 
p75
NTR−/− lung, when compared with the wt lung. Images 
are representative of n = 10 wt and n = 9 p75
NTR−/− 
mice. Western blots have been performed for n = 4 wt 
and n = 4 p75
NTR−/− mice. Bar: 150 μm (a–c), 75 μm 
(a–c, inset), 200 μm (d–f), 150 μm (g–i).JCB • VOLUME 177 • NUMBER 6 • 2007  1128
muscle cell apoptosis (Kraemer, 2002). In the sciatic nerve 
p75
NTR appears to have a dual role by sustaining fi  brin deposi-
tion (our study), and also promoting myelination (Cosgaya et al., 
2002; Song et al., 2006). Examination of functional recovery 
in p75
NTR−/− mice after peripheral nerve injury would reveal 
the contribution of p75
NTR-mediated ECM remodeling and re-
myelination to the regeneration process. Overall, the biological 
role of p75
NTR after tissue injury would probably depend on the 
relative contributions of its role as a regulator of cell death and 
differentiation and its role as an inhibitor of fi  brinolysis.
We identify regulation of cAMP as a novel signaling me-
chanism downstream of p75
NTR. Previous studies showed that 
β2-adrenergic receptors target degradation of cAMP to the mem-
brane via recruitment of multiple PDE4 isoforms, such as 
PDE4B1, PDE4B2, and PDE4Ds (Perry et al., 2002). Our fi  nding 
of interaction between p75
NTR and PDE4A4/5 represents the 
fi  rst example of recruitment of a single PDE4 isoform to a trans-
membrane receptor. While interaction of β2-adrenergic recep-
tors with PDE4s is mediated via β-arrestin, our study suggests 
that the interaction of p75
NTR with PDE4A4/5 could be poten-
tially mediated by direct binding to PDE4A domains, such as 
the C-terminal domain that is unique to this sub-family. In addi-
tion, in co-IP experiments we do not detect an interaction be-
tween p75
NTR and β-arrestin (unpublished data). It is possible 
that the unique C-terminal domain of PDE4A could regulate 
isoform-specifi  c PDE4 recruitment to subcellular locations. 
Biological roles have been described for PDE4D in ischemic 
stroke (Gretarsdottir et al., 2003) and heart failure (Lehnart et al., 
2005) and for PDE4B in schizophrenia (Millar et al., 2005). Our 
study identifi  es a biological function for PDE4A4/5 as a molec-
ular mediator of p75
NTR/cAMP/PKA signaling involved in the 
regulation of tPA and fi  brinolysis.
In spinal cord injury in rodents, elevation of cAMP via the 
PDE4 inhibitor, rolipram, promotes axonal regeneration and 
functional recovery (Nikulina et al., 2004). In the sciatic nerve, 
reduction of cAMP after injury is attributed primarily to up-
  regulation of PDE4 by SCs (Walikonis and Poduslo, 1998). 
Based on our fi  ndings, it is possible that reexpression of p75
NTR 
after injury could contribute to the activation of PDE4 and 
down-regulation of cAMP. BDNF, but not NGF, increases 
cAMP in neurons via TrkB (Gao et al., 2003). Moreover, BDNF/
TrkB signaling overcomes the inhibition of nerve regeneration 
by myelin proteins via inhibition of PDE4 (Gao et al., 2003). 
We provide the fi  rst evidence for p75
NTR in the regulation of 
cAMP by using genetic depletion, siRNA knockdown or up-
regula  tion of the p75
NTR. Our results suggest that p75
NTR might 
exert the opposite function as Trk receptors by recruiting 
PDE4A4/5 and decreasing cAMP. Interestingly, PDE4A has 
been detected as the predominant PDE4 isoform at the cortico-
spinal tract (Cherry and Davis, 1999). Because p75
NTR can act 
as a coreceptor for NogoR, a mediator of the inhibition of 
nerve regeneration, PDE4A interaction with p75
NTR could play 
an inhibitory role in nerve regeneration by competing with neuro-
trophin signaling via Trk receptors.
It is possible that the increased expression of p75
NTR by 
neurons, glia, and brain endothelial cells could regulate the tem-
poral and spatial pattern of tPA expression during brain injury 
or infl  ammation. p75
NTR might also be upstream of other non-
 fi brinolytic functions associated with tPA, such as neurodegener-
ation, synaptic plasticity, and long-term potentiation (Samson 
and Medcalf, 2006). Given the dependence of p75
NTR func-
tions on the availability of ligands and coreceptors (Teng and 
Hempstead, 2004; Reichardt, 2006), further analysis will deter-
mine the role of p75
NTR in extracellular proteolysis and ECM 
remodeling in different cellular systems. We show that expression 
of p75
NTR can inhibit tPA in the absence of neurotrophin ligands. 
Constitutive expression of p75
NTR may signal in a neurotrophin-
independent manner to induce neuronal apoptosis (Rabizadeh 
et al., 1993), activation of Akt (Roux et al., 2001), and RhoGTPase 
(Yamashita et al., 1999). The regulation of cAMP identifi  ed 
here is an effect of expression of p75
NTR that does not appear 
to depend on neurotrophin signaling. The cellular distribution 
of PDE4A4/5 would determine the involvement of p75
NTR 
in the regulation of cAMP. It is possible that non-neurotrophin 
ligands that bind directly to p75
NTR, such as β-amyloid (Teng 
and Hempstead, 2004), as well as the myelin/NogoR p75
NTR–
dependent inhibitors of nerve regeneration (Filbin, 2003), are able 
to regulate both cAMP and plasminogen activation by p75
NTR. 
Because cAMP analogues decrease expression of p75
NTR (Baron 
et al., 1997), it is possible that p75
NTR by decreasing cAMP con-
tributes to the positive regulation of its expression. Because PKA 
phosphorylates p75
NTR and regulates its translocation to lipid 
rafts (Higuchi et al., 2003), p75
NTR via regulation of PKA might 
regulate its own subcellular localization. Given the multiple 
genes regulated by cAMP and PKA, other cellular functions 
may be regulated by p75
NTR/cAMP signaling.
Figure 10.  Proposed model for the role of p75
NTR in the 
cAMP-mediated plasminogen activation. p75
NTR interacts 
with PDE4A4/5 resulting in degradation of cAMP and 
thus a reduction of PKA activity. Decrease in cAMP re-
duces expression of tPA and increases PAI-1, resulting in 
reduction of plasmin and plasmin-dependent extracellular 
proteolysis. Reduction of plasmin results in reduced ﬁ  brin 
degradation and ECM remodeling. Because plasmin can 
proteolytically modify nonﬁ  brin substrates, such as growth 
factors and cytokines, this mechanism may be upstream of 
various cellular functions. P75
NTR TARGETS CAMP DEGRADATION TO THE MEMBRANE AND REGULATES FIBRINOLYSIS • SACHS ET AL. 1129
NGF/p75
NTR signaling has been suggested to enhance lo-
cal neurogenic infl  ammation to exacerbate pulmonary disease 
(Renz et al., 2004). Our study suggests an additional pathway 
for p75
NTR as a regulator of expression of PAI-1 and a mediator 
of fi  brosis. p75
NTR in the lung is detected mainly in basal epithe-
lial cells of bronchioles (unpublished data). Similar to p75
NTR, 
PAI-1 is expressed by bronchial epithelial cells (Savov et al., 
2003) and its expression results in an antifi  brinolytic environ-
ment within the airway wall. Fibrin regulates both infl  ammation 
and airway remodeling (Idell, 2003; Savov et al., 2003). It is 
therefore possible that p75
NTR-mediated regulation of PAI-1 via 
PDE4 could infl  uence infl  ammatory and tissue repair processes 
in pulmonary disease. Although in chronic obstructive pulmo-
nary disease the PDE4A4 isoform is specifi  cally up-regulated 
(Barber et al., 2004) and considered a pharmacologic target 
(Houslay et al., 2005), all available inhibitors target the com-
mon catalytic domain of all PDE4 isoforms resulting in un-
wanted side-effects. Our study suggests that the p75
NTR/PDE4A4 
interaction could be a potential therapeutic target that will 
achieve the specifi  c inhibition of a single PDE4 isoform and 
may have therapeutic potential.
Collectively, we have identifi  ed a novel cAMP-dependent 
signaling pathway initiated by p75
NTR that specifi  cally regu-
lates plasminogen activity and scar formation after sciatic nerve 
and lung injury. Though p75
NTR is responsible for a variety of 
cell survival and death decisions (Chao, 2003), our data has re-
vealed an unrecognized property of this receptor to regulate the 
degradation of cAMP. This property provides a potential mech-
anism to account for how p75
NTR acts at sites of injury to pro-
mote ECM remodeling. The impact of high levels of p75
NTR 
expression upon inhibition of extracellular proteolysis indi-
cates that the detrimental effects of p75
NTR extend beyond cell 
growth and axon inhibition. Finally, the dramatic inhibitory 
  effect of p75
NTR signaling on plasminogen activation sug-
gests that the p75
NTR/PDE4A4 interaction represents a novel 
target for therapeutic intervention in both neuronal and non-
neu ronal tissues.
Materials and methods
Animals, sciatic nerve crush, and induction of lung ﬁ  brosis
p75
NTR−/− mice (Lee et al., 1992) and tPA
−/− mice (Carmeliet et al., 1994) 
were in C57Bl/6 background and purchased from The Jackson Laboratory. 
Double p75
NTR−/−tPA
−/− mice were generated by crossing p75
NTR−/− mice 
with tPA
−/− mice. C57Bl/6J mice were used as controls. Sciatic nerve 
crush was performed as described previously (Akassoglou et al., 2000). 
Lung ﬁ  brosis was induced as described previously (Chen et al., 2004). 
For the rolipram treatments, mice were administered 5 mg/kg rolipram 
(Calbiochem) before the LPS injection as described previously (Miotla 
et al., 1998). Mice were killed 4.5 h after LPS or saline administration. For 
rolipram treatment after sciatic nerve injury, mice were injected with roli-
pram (1 mg/kg) once daily for 8 d until tissue was harvested and pro-
cessed for immunostaining.
Immunohistochemistry
Immunohistochemistry was performed as described in Akassoglou et al. 
(2002). Primary antibodies were sheep anti    –human ﬁ  brin(ogen) (1:200; 
US Biologicals), rabbit anti–human tPA (1/300; Molecular Innovations), 
rabbit anti-p75
NTR clone 9651, (1:1,000), goat anti-p75
NTR (1/200; Santa 
Cruz Biotechnology, Inc.), rabbit anti–mouse PAI-1 (1:500; a gift from 
  David Loskutoff, Scripps Research Institute, La Jolla, CA), and mouse anti-
S100 (1:200; Neomarkers). For immunoﬂ  uorescence, secondary antibodies 
were anti–rabbit FITC and anti–goat Cy3 (1:200; Jackson Immunochemicals). 
Images were acquired with an Axioplan II epiﬂ  uorescence  microscope 
(Carl Zeiss MicroImaging, Inc.) using dry Plan-Neoﬂ  uar lenses using 10× 
0.3 NA, 20× 0.5 NA, or 40× 0.75 NA objectives equipped with 
Axiocam HRc digital camera and the Axiovision image analysis system.
Immunoblot
Immunoblot was performed as described previously (Akassoglou et al., 
2002). Antibodies used were rabbit anti-p75
NTR clones 9992 and 9651 
(1:5,000), mouse anti-ﬁ   brin (1:500; Accurate Chemical & Scientiﬁ  c 
Corp.), rabbit anti-myosin (1:1,000; Sigma-Aldrich), rabbit anti-GAPDH 
(1:5,000; Abcam) and rabbit anti-PAI-1 (1:5,000; a gift of David Loskutoff). 
Quantiﬁ  cation was performed on the Scion NIH Imaging Software. Fibrin 
precipitation and quantiﬁ  cation from lung tissues was performed exactly as 
described previously (Ling et al., 2004).
Co-IP
Co-IP was performed as described previously (Khursigara et al., 1999). 
Cell lysates were prepared in 1% NP-40, 200 mM NaCl, 1 mM EDTA, and 
20 mM Tris-HCl, pH 8.0. IP was performed with an anti-p75
NTR antibody 
(9992) and immunoblot with anti-PDE4A, PDE4B, PDE4C, and PDE4D 
(Fabgennix). The co-IP buffer using NP-40 has been previously used to ex-
amine interactions of p75
NTR with other intracellular proteins, such as TRAF-6 
(Khursigara et al., 1999) and PKA (Higuchi et al., 2003). For mapping 
  experiments, PDE4A5 cDNA was cotransfected with HA-tagged p75
NTR 
deletion constructs into HEK293 cells. IP was performed with an anti-HA 
antibody (Cell Signaling). Cell lysates were probed with an anti-PDE4A or 
an anti-p75
NTR antibody (9651). For co-IP experiments using recombinant 
proteins, equimolar amounts (2 μM) of puriﬁ  ed recombinant MBP-PDE4A5 
(O’Connell et al., 1996), MPB-PDE4A4 (McPhee et al., 1999), MBP-
PDE4D3 (Yarwood et al., 1999), and GST-p75
NTR-ICD (Khursigara et al., 
2001) were mixed in binding buffer (50 mM Tris-HCl, pH 7.5, 100 mM 
NaCl, 2 mM MgCl2, 1 mM DTT, 0.5% Triton X-100, and 0.5% BSA) and 
incubated for 1 h at 4°C. Washed glutathione-Sepharose beads were 
added according to the manufacturer’s instructions for an additional hour. 
Beads were sedimented by centrifugation (10,000 g for 1 min) and washed 
three times. Proteins associated with the beads were eluted by boiling in 
loading buffer and separated by SDS-PAGE.
RT-PCR and real-time PCR
RT-PCR was performed as described previously (Akassoglou et al., 2002). 
Primers for tPA, uPA, and PAI-1 genes were used as described previously 
(Yamamoto and Loskutoff, 1996). Real-time PCR was performed using 
the Opticon DNA Engine 2 (MJ Research) and the Quantitect SYBR 
Green PCR kit (QIAGEN). Results were analyzed with Opticon 2 soft-
ware using the comparative Ct method as described previously (Livak and 
Schmittgen, 2001). Data were expressed as ∆∆Ct for the tPA gene nor-
malized against GAPDH.
Quantiﬁ  cation of tPA and uPA activity
Quantiﬁ  cation of tPA and uPA activity in SC and ﬁ  broblast in lysates and 
supernatants was performed according to the directions of the activity as-
say kits from American Diagnostica and Chemicon, respectively. To elevate 
cAMP cells were treated either with 2 mM db-cAMP (Sigma-Aldrich) or with 
10 μM forskolin (Sigma-Aldrich) for 16 h. To block PKA activity, cells were 
treated with 200 nM KT5720 (Calbiochem). Induction with neurotrophins 
was performed using 100 ng/ml NGF and 50 ng/ml BDNF for 16 h before 
tPA assay.
Fibrin degradation assay
Coating with ﬁ  brin was prepared as described previously (Lansink et al., 
1998). To quantitate ﬁ   brin degradation, the supernatant was aspirated 
and the remaining gel was weighed using an analytical balance. Decrease 
of gel weight corresponded to increased ﬁ  brin gel degradation.
Cell culture and transfections
Murine SCs were isolated as described previously (Syroid et al., 2000). 
NIH3T3 or HEK293 cells were cotransfected either with p75
NTR FL, ICD 
or deletion constructs, and PDE4A5 cDNAs using Lipofectamine 2000 
(Invitrogen) as described in the Results section. CGNs were isolated 
from P10 animals (Yamashita and Tohyama, 2003). CGNs were lysed 
immediately for co-IP, without plating. siRNA directed against p75
NTR 
(Dharmacon) was transfected into SCs and NIH3T3p75
NTR cells using 
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6 ﬁ broblasts or 500,000 SCs were lysed in 0.1 N HCl solution and cAMP 
was measured using a competitive binding cAMP ELISA (Assay Designs). 
Cells were treated with 100 ng/ml PTX for 16 h. For inhibition of PDE activity, 
cells were treated for 16 h with 500 μM isobutyl methylxanthine (IBMX; 
Calbiochem), 18.7 μM 8-methoxymethyl-3-isobutyl-1-methylxanthine (PDE1 
inhibitor; Calbiochem), 80 μM erythro-9-(2-Hydroxy-3-nonyl)adenine (PDE2 
inhibitor; Calbiochem), 100 nM trequinsin (PDE3 inhibitor; Calbiochem), 
and 10 μM rolipram (PDE4 inhibitor; Calbiochem). Cells were treated with 
forskolin in the presence of the inhibitors for 1 h. Because these inhibitors 
speciﬁ  cally inhibit a PDE isoform and have no effect on the other PDE iso-
enzymes (Beavo and Reifsnyder, 1990), they are extensively used for the 
identiﬁ  cation of the speciﬁ  c PDE isoform that is involved in different cellular 
functions. Induction with neurotrophins was performed using 100 ng/ml 
NGF or 50 ng/ml BDNF, 750 ng/ml of FcTrkB, or 1.35 ug/ml of Fcp75
NTR 
for 1 h before cAMP assay. For the qualitative and quantitative PKA assay 
(Promega), cells were treated with 10 μM forskolin for 30 min, lysed in 1% 
NP-40 buffer with 150 mM NaCl, 50 mM Tris, and 1 mM EGTA, and pro-
tein concentration was determined using the Bradford Assay (Bio- Rad Labo-
ratories). 1 μg was loaded into the PKA assay reaction mix according to the 
manufacturer’s protocol (Promega).
In situ zymography
In situ zymographies were performed as described previously (Akassoglou 
et al., 2000). Quantiﬁ  cation of in situ zymographies was performed by 
measuring the area of the lytic zone surrounding each nerve, and dividing 
that value by the area of the nerve. Images were collected after 8 h of incu-
bation for the sciatic nerve and 4 h of incubation for the lung. For cell 
zymographies, cultures were washed four times with PBS/BSA and overlaid 
with 200 μl of Dulbecco’s minimum essential medium containing 1% LMP 
agarose, 2.5% boiled nonfat milk, and 25 μg/ml human plasminogen. 
The overlay was allowed to harden, and plates were incubated in a cell 
culture incubator at 37°C. Pictures of lytic zones were taken using an 
  inverted microscope under dark ﬁ  eld (Carl Zeiss MicroImaging, Inc.).
Construction of pm-AKAR2.2 and PDE4A4𝗅CT
For the construction of pm-AKAR2.2 we used the previously described cyto-
plasmic PKA sensor, AKAR2 (Zhang et al., 2005). pm-AKAR2.2 consists of 
a cDNA containing a FRET pair, monomeric enhanced cyan ﬂ  uorescent pro-
tein (ECFP), and monomeric citrine (an optimized version of YFP), fused to 
forkhead associated domain 1 (FHA1) (Rad53p 22–162), and the PKA sub-
strate sequence LRRATLVD via linkers. A206K mutations were incorporated 
to ECFP and Citrine by the QuikChange method (Stratagene). The C-terminal 
sequence from K-Ras K  K  K  K  K  K  S  K  T  K  C  V  I  M   was added to target the construct 
to the plasma membrane. For expression in mammalian cells, the chimaeric 
proteins were subcloned into a modiﬁ  ed pcDNA3 vector (Invitrogen) behind 
a Kozak sequence as described previously (Zhang et al., 2005).
For the generation of the PDE4A4δCT, PDE4A4 was subcloned into 
p3XFLAG-CMV-14 using plasmid pde46 (GenBank/EMBL/DDBJ acces-
sion no. L20965) as template from Met-1 to Iso-721 (McPhee et al., 1999). 
A forward (5′) primer containing a HindIII restriction site immediately 5′ to 
the initiating Met-1 (ATG) of PDE4A4 and a reverse primer designed to the 
DNA sequence ending at Iso-721 (ATA) with BamHI restriction site immedi-
ately 3′ to Iso-721 was used to amplify Met-1 to Iso-721. The C terminus 
was removed simply by amplifying from Iso-721 instead of the ﬁ  nal codon 
at the end of the full-length PDE4A4B. The C-terminally truncated PDE4A4B 
was cloned in-frame with three FLAG (Asp-Tyr-Lys-Xaa-Xaa-Asp) epitopes 
(Asp-726, Asp-733 & Asp-740) after the BamHI restriction site, therefore at 
the C terminus of the now-truncated PDE4A4. The stop codon (TAG) after 
the FLAG epitopes is located immediately after Lys-747. This strategy gen-
erates a C-terminal truncate of PDE4A4 from 1–721.
FRET imaging
NIH3T3 cells and NIH3T3p75
NTR cells were transiently transfected with 
pm-AKAR2.2, AKAR3, or pm-AKAR3 (Allen and Zhang, 2006) and im-
aged within 24 h of transfection. Cells were rinsed once with HBSS (Cellgro) 
before imaging in HBSS in the dark at room temperature. An Axiovert 
microscope (Carl Zeiss Microimaging, Inc.) with a MicroMax digital camera 
(Roper-Princeton Instruments) and MetaFluor software (Universal Imaging 
Corp.) was used to acquire all images. Optical ﬁ  lters were obtained from 
Chroma Technologies. CFP and FRET images were taken at 15-s intervals. 
Dual emission ratio imaging used a 420/20-nm excitation ﬁ  lter, a 450-nm 
dichroic mirror and a 475/40-nm or 535/25-nm emission ﬁ  lter for CFP 
and FRET, respectively. Excitation and emission ﬁ  lters were switched in ﬁ  lter 
wheels (Lambda 10–2; Sutter Instrument Co.).
Peptide array mapping
Peptide libraries were synthesized by automatic SPOT synthesis (Frank, 
2002). Synthetic overlapping peptides (25 amino acids in length) were 
spotted on Whatman 50 cellulose membranes according to standard pro-
tocols by using Fmoc-chemistry with the AutoSpot Robot ASS 222 (Intavis 
Bioanalytical Instruments AG). Membranes were overlaid with 10 μg/ml 
recombinant GST-p75
NTR ICD. Bound recombinant GST-p75
NTR ICD (Khursi-
gara et al., 2001) was detected using rabbit anti-GST (1:2,000; GE 
Healthcare) followed by secondary anti–rabbit horseradish peroxidase 
  antibody (1:2,500; Dianova). Alanine scanning was performed as described 
previously (Bolger et al., 2006).
Statistics
Statistical signiﬁ  cance was calculated using JMP2 Software by unpaired 
t test for isolated pairs or by analysis of variance (one-way ANOVA) for mul-
tiple comparisons. Data are shown as the mean ± SEM.
Online supplemental material
Fig. S1 shows that genetic loss of p75
NTR increases tPA mRNA levels and 
proteolytic activity in the cerebellum. Fig. S2 demonstrates that treatment 
with neurotrophins has no effect on cAMP levels in NIH3T3 cells. Fig. S3 
shows endogenous coimmunoprecipitations of PDE4A5 and p75
NTR from 
injured sciatic nerve and from primary CGNs. Fig. S4 shows results from 
transient transfections of NIH3T3 cells with p75
NTR and the PKA activity 
reporters, AKAR3 and pm-AKAR3. Fig. S5 shows that inhibition of PDE4s 
with rolipram decreases ﬁ  brin deposition both in LPS-induced lung ﬁ  brosis 
and sciatic nerve crush injury. The online version of this article is available 
at http://www.jcb.org/cgi/content/full/jcb.200701040/DC1.
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